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Oral Presentations S159Relapse rates in patients (pts) after autologous stem cell transplant
(SCT) for high risk or refractoryNHL remains high. Our preclinical
studies showed that activated T cells (ATC) armed with anti-CD3 x
anti-CD20 bispecific antibody (CD20Bi) lyse rituximab-resistant
CD201 lymphoma cells. A phase I trial was conducted in 15 high
risk or refractory NHL pts to determine the safety of armed ATC
(aATC) given after SCT and whether aATC infusions accelerate im-
mune recovery and provide an anti-lymphoma effect. Leukopheresis
products were activated with anti-CD3, expanded in IL-2, armed
with CD20Bi, and cryopreserved for infusions after SCT. At the
time of SCT, there were 6 pts in 1st or 2nd remission (CR), 4 pts
had refractory disease (PRD), 4 pts were in partial response, and 1
pt had progressive disease (PD). Pts received 5-20  109 aATC
per infusion. The first 3 patients received 5x109 three times per
week for 3 weeks and then once per week for 6 weeks for a total
aATC dose of 75x109. Subsequently, the schedule was revised to 1
infusion/week for 4 weeks with infusion doses of 10, 15, and
20x109 aATC. The median dose of CD341 cells/kg infused was
4.0x106(1.04-12.3x106). The ATC product was 92% viable, con-
tainedmedians of 96.5%CD3, 67%CD4, and 48.9%CD8 cells. Fif-
teen pts received aATC and 12 were evaluable for toxicities. The
Table 1 summarizes grade 1-3 events.
Table 1. Grade-1-3 Events
Dose 5 billion 10 billion 15 billion 20 billionPts Number 3 3 3 3
Infusions 15 4 4 4
Fever 3 10 12 12
Chills 2 7 3 4
Malaise 1 2 7 11
Hypotension 3 4 1 5
Tachycardia 3 2 5 4
Nause/vomiting 0 7 3 4
Headache 0 2 2 2
Dyspnea 1 0 0 0
Hypoxia 0 0 0 1(NCI Immunotherapy Criteria).
The median day to engraftment was 14.75 days without G-CSF.
aATC could be detected by flow cytometry up to 12 hours after in-
fusion. The proportions of CD4 cells were in the normal range up to
a month. There was a . 4x increase in the mean (6SD) number of
IFNg EliSpots in response to Daudi cells from 30.5620.5/106
PBL preSCT to 125.66130/106PBL post SCT, p\0.008. The me-
dian cytotoxicity mediated by NK cells ranged from 8.2-13.7% be-
tween 2 weeks and 3 months after SCT. Serum cytokines and
chemokines peaked around 4 hrs after aATC infusions with 1-2
log increases in IL-2, IL-7, IL-15, IL-2r, MIP-1b, IP10, MIP-1a,
MIG, and MICP-10. At 90 days after SCT, 9 pts were in CR and
6 pts had PD. The median OS has not been reached and OS is pro-
jected to be 55% at 4 years. Pts in CR prior to SCT had longer sur-
vival at 85% with no relapses after 1 year after SCT. These findings
show that: 1) ATC can be expanded from heavily pretreated NHL
pts; 2) aATC infusions are safe; 3) induce high levels of serum cyto-
kines and chemokines; and 4) may provide anti-tumor help and cyto-
toxicity after SCT.24
COMBINING AZACITIDINE (VIDAZA, AzA) AND DONOR LYMPHOCYTE
INFUSIONS (DLI) AS FIRST SALVAGE TREATMENT IN PATIENTS (PTS)
WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYN-
DROMES (MDS) RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION (Allo-SCT): INTERIM-ANALYSIS FROM
THE AZARELA-TRIAL (NCT-00795548)
Schroeder, T.1, Czibere, A.G.1, Kr€oger, N.2, Platzbecker, U.3, Bug, G.4,
Uharek, L.5, Luft, T.6, Bruns, I.1, Zohren, F.1, Wolschke, C.2,
Fenk, R.1, Haas, R.1, Kobbe, G.1 1Heinrich Heine University, Medical
Faculty, Duesseldorf, Germany; 2University Cancer Centre, Hamburg,
Germany; 3University Hospital Dresden, Dresden, Germany; 4Universityof Frankfurt, Frankfurt, Germany; 5Charite Campus Benjamin Frank-
lin, Berlin, Germany; 6University of Heidelberg, Heidelberg, Germany
Prognosis for pts with AML/MDS relapsing after allo-SCT is
poor and therapeutic options are limited. Results from recent retro-
spective analyses on the use of Aza1/- DLI in pts with AML/MDS,
who relapsed after allo-SCT, were encouraging.
To evaluate the potential of Aza combined with DLI as 1st sal-
vage therapy in pts with AML/MDS relapsing after allo-SCT we
conducted a prospective phase-II multicenter trial. Pts were al-
lowed to receive up to 8 cycles Aza (100 mg/m2/d d1-5, every 28
d) and 3 DLI with increasing dosages (1-5x106–1-5x108 cells/kg)
after every 2nd Aza cycle. So far, 25 pts (15 f/10 m) are evaluable
for this analysis.
At diagnosis 23 (92%) had AML (15 de novo/8 followingMDS), 1
(4%) MDS (RAEB-1) and 1 (4%) MDS/MPS (CMML-1). Based on
cytogenetics 21 pts belonged to an adverse or intermediate risk
group, whereas 2 pts had favorable cytogenetics (2 n.p.).
At transplant, 6 pts (24%) had induction failure, 6 (24%) suffered
from 1st or 2nd relapse, 10 pts (40%) were in 1st or 2ndCR, while 3 pts
(12%) were untreated. Eight pts (35%) received grafts from MSD
and 15 (65%) from MUD (2 pts missing data). PBSC were used in
24 pts (96%; 1 missing). Prior to relapse 9 (36%) and 3 (12%) pts
had episodes of aGvHD and/or cGvHD, respectively.
At relapse, 4 (31%) of 13 evaluable pts had normal cytogenetics,
while 9 (69%) had chromosomal aberrations including 6 pts (46%)
with complex karyotype. Relapse occurred in median 160 d (range
19-1199) after allo-SCT (BM blasts 34%, range 5-100%, donor
chimerism 63% range 1-100%). Median age was 54 y (range 29-
71). Patients received a median of 3 cycles Aza (range 1-8) and 18
pts (72%) received DLI (median: 1, range 1-4, median CD3 dose
5x106/kg/DLI, range 1-207x106).
Overall response rate was 64% with 5 pts (20%) achieving CR/
CRi, 3 (12%) PR and 8 (32%) SD. Median response duration was
266 d. Acute GvHD occurred in 6 pts (24%) (2 skin/6 liver/ 2 gut)
after a median of 65 d (range 19-179) following the 1st DLI. Three
pts (12%) had limited cGvHD. Hematotoxicity IIIo-IVo was
observed in 64%. Common adverse events were gastrointestinal
side effects and infections. After a median follow-up of 100 d (range
25-485) 15 pts (60%) are alive. Median OS of all pts is 184 d (range
87-281). All pts, who achieved a CR/CRi, remained in ongoing
remission for a median of 229 d.
Our data suggest that salvage therapy with Aza1DLI for pts with
AML/MDS relapsing after allo-SCT is feasible and has significant
anti-leukemic activity in these pts.GRAFT PROCESSING25
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Up to 30% of patients fail to collect minimum numbers of PBSC
for ASCT, and up to 50% of patients fail to collect the optimal num-
ber. Plerixafor, a CXCR4 antagonist, in combination with G-CSF
has shown superior results inmobilizing PBCD341 cells in compar-
ison to G-CSF alone for autologous PBSC mobilization in patients
with NHL or MM. However, due to its high cost, we commenced
a risk adapted algorithm for the utilization of plerixafor starting in
Feb 2009.
Jan-Dec 2008 was the baseline. Patients in upfront mobilization
clinical trials with plerixafor were excluded. From Feb-Nov 2009,
the risk adapted algorithmPlerixafor-1was used. PBSCmobilization
was commenced with G-CSF at 10 mcg/kg/day. If PB CD34 on day
4 or day 5 was$ 10/mL, apheresis was commenced the next morning.
S160 Oral PresentationsIf PB CD34 was\ 10/mL on day 5, plerixafor (0.24 mg/kg sc) was
administered in the evening 5 and apheresis was commenced the
next day. If daily yield was \ 0.5  106CD34/kg, plerixafor was
added. In Dec 2009, the algorithm was changed to Plerixafor-2.
The dosing of G-CSF and plerixafor remained the same, however
the thresholds changed to if day 4 PB CD34 \ 10 for single or
\20/mL for multiple transplants, plerixafor was added. If day 1 yield
was\1.5  106 CD34/kg, or any subsequent daily yield was\ 0.5,
plerixafor was added.
In the 3 time periods, Jan-Dec 2008, there were 327 mobiliza-
tion attempts in 286 patients, Feb-Nov 2009, 228 mobilization at-
tempts in 224 pts, and Dec 2009-June 2010, 101 attempts in 100
pts. Costs of the mobilization and collection included drugs costs
(cyclophosphamide, G-CSF, GM-CSF and plerixafor), apheresis
and cryopreservation. Supportive care costs of transfusions, anti-
biotics, hospitalizations, nursing costs and patients personal costs
were not included. The details of the results are outlined in the
table. Plerixafor-2 shows a statistical improvement PBSC collec-
tions, increased number of patients reaching minimum and opti-
mal goals, less days of apheresis and total days of mobilization/
collection.
In conclusion, although the earlier identification of ineffective
PBSC mobilization and initiation of plerixafor (Plerixafor-2) in-
creases the costs of PBSC mobilization, more patients are able to
achieve the minimum and optimal goals of CD34 collection, failure
rates, number of days of apheresis and total days of mobilization/
collection are lower. It is unclear if upfront mobilization with plerix-
afor 1 G-CSF would result in further benefit.
Table 1. Results of Mobilization and Collection
Baseline2008 Plerixafor-1 Plerixafor-2 P valuePatients 286 224 100Mobilization
Attempts/
Remobilizations327/ 41 (14%) 228/ 4 (2%) 101/ 1 (1%)CD34 collected
- x106/kgMedian 5.34 6.04 7.72 <0.001Range 0-25.8 0.1-28.2 1.48-29.3Mean 5.66 6.86 8.16Collections
>4 x106/kg (%)223 (68%) 185 (81%) 93 (92%) <0.001Collections
>2x106/kg(%)261 (80%) 212 (93%) 99 (97%) <0.001Mobilization Failures 66 (20%) 16 (7%) 1 (1%) <0.001Days of ApheresisMedian 2 3 2 0.002Range 0-11 1-12 1-9Mean 2.6 3.1 2.5Total Days of
Mobilization/
CollectionMedian 8 8 6Range 4-28 4-25 4-22Mean 9 8.9 7.2 <0.001Total Cost
per patientMedian $12 500 $12 500 $21 000 <0.001Minimum $3000 $5000 $5500Maximum $146 750 $93 500 $89 750Mean $17 300 $21 686 $20 695Plerixafor Use 29 # (9%) 94 (41%) 60 (59%)Days- Median 5 3 2 <0.001Range 1-10 1-8 1-9Mean 5 3.3 2.6Bone Marrow
Harvest*3 0 0#All remobilizations were on the compassionate use protocol. Costs
were based on current pricing of plerixafor;
*Cost of bone marrow harvest not inclusded in costs per patient.GVH/GVL
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Cdk5 is a ubiquitously expressed serine/threonine kinase. Cdk5
and its obligate partners p35 and p39 are required for neuronal de-
velopment and migration. Activation of the Cdk5/p35 complex is as-
sociated with inflammatory disorders, but the contribution of Cdk5
activity to T cell activation has not been explored. Using a mouse
BMT model (B6/ B6D2F1), we reveal a critical role for Cdk5 in
the induction of GVHD.TCR stimulation leads to a rapid induction
of Cdk5/p35 expression and function, and Cdk5 activity is increased
in the spleen and intestine of mice with GVHD. To study the role of
Cdk5 in T cells, we generated chimeric mice (Cdk52/2C) by recon-
stituting irradiated B6mice with hematopoietic progenitors from the
liver and spleen of E16.5 Cdk51/1 and Cdk52/2 littermate embryos;
germ line deletion of the Cdk5 gene is embryonically lethal. BMT
using B6 Cdk52/2C donors and lethally irradiated F1 hosts resulted
in a dramatic reduction in mortality (25% vs. 92%) and systemic
GVHD (p \ 0.01) compared to mice receiving B6 Cdk51/1C
BMT. Similar findings were seen in GVHD across an isolated
MHC-II mismatch, but were less apparent in a MHC class I dispa-
rate model, suggesting that Cdk5 was functioning primarily through
CD41 T cells. Mixing studies in the B6/F1 model showed that
CDk5 expression in purified T cells (compared to BM) was predom-
inantly responsible for reduced GVHD, and while a survival advan-
tage was maintained in GVL experiments, Cdk52/2C BMT was
associated with more leukemic deaths. Functional characterization
of Cdk52/2C T cells showed modest reductions in T cell prolifera-
tion to host antigens, but no differences in cytokine production or
CTL activity. However, donor splenic T cell numbers were mark-
edly reduced on days 7, 10 and 14 after Cdk52/2C BMT (p \
0.01), findings that were associated with reductions in day 7 serum
IFNg levels. Further studies showed that Cdk5 phosphorylates the
actin modulator Coronin 1a on threonine 418. Activated Cdk52/2
T cells lack this post-translational modification, exhibit defective
TCR-induced actin polarization and reduced migration towards
CCL-19.Co-migration studies using flow cytometry and intravitalmi-
croscopy revealed significant reductions in homing of Cdk52/2C
T cells (CD4 . CD8) to spleen and lymph nodes, but once entered,
the migration speed of Cdk52/2 T cells was not altered. Collectively,
our data define a novel role for Cdk5 in lymphocyte biology and allo-
geneic T cell responses after BMT.27
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Background: In 2005, the NIH Consensus Project proposed the
cGVHD severity score to standardize clinician evaluation and stag-
ing of cGVHD.This analysis was conducted to validateNIH scoring
variables as adequate determinants of disease severity.
Methods: 189 adults were enrolled on the prospective NCI cross-
sectional cGVHDnatural history study between 2004-2010.Median
age was 46 yrs (18–70), median time from transplant was 35 mos
